Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karol Granados

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|November 10, 2020
Cellular Reprogramming-A Model for Melanoma Cellular PlasticityKarol Granados, Juliane Poelchen, Daniel Novak, et al.
Oncotarget|January 5, 2018
New role of ID3 in melanoma adaptive drug-resistanceSachindra, Lionel Larribère, Daniel Novak, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2023
eIF2Bδ blocks the integrated stress response and maintains eIF2B activity and cancer metastasis by overexpression in breast cancer stem cellsMalavika Gupta, Beth A Walters, Olga Katsara, et al.
International Journal of Cancer|August 16, 2018
Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulationHuizi Wu, Lionel Larribère, Qian Sun, et al.
International Journal of Cancer|June 16, 2018
SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanomaLaura Hüser, Sachindra Sachindra, Karol Granados, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2026
AUF1 therapy blocks atrophy, promotes regeneration, re-innervation and strength for severe muscle injuryDounia Abbadi, Olga Katsara, Riley McConnell, et al.
International Journal of Cancer|April 10, 2021
FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factorQian Sun, Daniel Novak, Laura Hüser, et al.
Cancers|December 17, 2020
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in MelanomaLaura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, et al.
International Journal of Cancer|May 28, 2019
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic targetElias Orouji, Aniello Federico, Lionel Larribère, et al.
British Journal of Cancer|February 18, 2020
T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cellsKarol Granados, Laura Hüser, Aniello Federico, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|November 10, 2020
Cellular Reprogramming-A Model for Melanoma Cellular PlasticityKarol Granados, Juliane Poelchen, Daniel Novak, et al.
Oncotarget|January 5, 2018
New role of ID3 in melanoma adaptive drug-resistanceSachindra, Lionel Larribère, Daniel Novak, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2023
eIF2Bδ blocks the integrated stress response and maintains eIF2B activity and cancer metastasis by overexpression in breast cancer stem cellsMalavika Gupta, Beth A Walters, Olga Katsara, et al.
International Journal of Cancer|August 16, 2018
Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulationHuizi Wu, Lionel Larribère, Qian Sun, et al.
International Journal of Cancer|June 16, 2018
SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanomaLaura Hüser, Sachindra Sachindra, Karol Granados, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 25, 2026
AUF1 therapy blocks atrophy, promotes regeneration, re-innervation and strength for severe muscle injuryDounia Abbadi, Olga Katsara, Riley McConnell, et al.
International Journal of Cancer|April 10, 2021
FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factorQian Sun, Daniel Novak, Laura Hüser, et al.
Cancers|December 17, 2020
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in MelanomaLaura Hüser, Marianthi-Maria Kokkaleniou, Karol Granados, et al.
International Journal of Cancer|May 28, 2019
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic targetElias Orouji, Aniello Federico, Lionel Larribère, et al.
British Journal of Cancer|February 18, 2020
T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cellsKarol Granados, Laura Hüser, Aniello Federico, et al.
Pageof 2